| Symbol | QNRX |
|---|---|
| Name | QUOIN PHARMACEUTICALS, LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Medical/Dental Instruments |
| Address | 42127 PLEASANT FOREST COURT, ASHBURN, Virginia, 20148-7349, United States |
| Telephone | +1 703 980-4182 |
| Fax | — |
| — | |
| Website | https://www.quoinpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001671502 |
| Description | Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. Additional info from NASDAQ: |
(30% Negative) QUOIN PHARMACEUTICALS, LTD. (QNRX) Reports Q3 2026 Financial Results
Read moreQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Read moreQuoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
Read moreNew Form ARS - Quoin Pharmaceuticals, Ltd. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0001104659-26-084081 <b>Size:</b> 17 MB
Read moreNew Form DEF 14A - Quoin Pharmaceuticals, Ltd. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0001104659-26-084078 <b>Size:</b> 3 MB
Read moreNew Form PRE 14A - Quoin Pharmaceuticals, Ltd. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001104659-26-080828 <b>Size:</b> 3 MB
Read moreQuoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Read moreQuoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Read moreQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Read moreQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07538583 | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Phase2 | Netherton Syndrome | Recruiting | 2026-03-19 | 2027-03-31 | ClinicalTrials.gov |
| NCT06953466 | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Phase2 | Netherton Syndrome | Recruiting | 2025-07-01 | 2026-07-30 | ClinicalTrials.gov |
| NCT05789056 | Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Nethert… | Phase2 | Netherton Syndrome | Recruiting | 2023-03-14 | 2025-12-30 | ClinicalTrials.gov |
| NCT05521438 | Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton S… | Phase2 | Netherton Syndrome | Active_Not_Recruiting | 2022-06-23 | 2026-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| QRX003, 4% Lotion | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT05789056 |
| QRX003, 4% Lotion | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT06953466 |
| QRX003-4% Lotion BID | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| Vehicle | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| QRX003-4% Lotion QAM | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| QRX003-2% Lotion | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |